Abstract
Purpose
This study aimed to study whether cancer cells possess distinguishing metabolic features compared with surrounding normal cells, such as increased glutamine uptake. Given this, quantitative measures of glutamine uptake may reflect critical processes in oncology. Approximately, 10 % of patients with colorectal cancer (CRC) express BRAF V600E, which may be actionable with selective BRAF inhibitors or in combination with inhibitors of complementary signaling axes. Non-invasive and quantitative predictive measures of response to these targeted therapies remain poorly developed in this setting. The primary objective of this study was to explore 4-[18F]fluoroglutamine (4-[18F]F-GLN) positron emission tomography (PET) to predict response to BRAFV600E-targeted therapy in preclinical models of colon cancer.
Procedures
Tumor microarrays from patients with primary human colon cancers (n = 115) and CRC liver metastases (n = 111) were used to evaluate the prevalence of ASCT2, the primary glutamine transporter in oncology, by immunohistochemistry. Subsequently, 4-[18F]F-GLN PET was evaluated in mouse models of human BRAF V600E-expressing and BRAF wild-type CRC.
Results
Approximately 70 % of primary colon cancers and 53 % of metastases exhibited positive ASCT2 immunoreactivity, suggesting that [18F]4-F-GLN PET could be applicable to a majority of patients with colon cancer. ASCT2 expression was not associated selectively with the expression of mutant BRAF. Decreased 4-[18F]F-GLN predicted pharmacological response to single-agent BRAF and combination BRAF and PI3K/mTOR inhibition in BRAF V600E -mutant Colo-205 tumors. In contrast, a similar decrease was not observed in BRAF wild-type HCT-116 tumors, a setting where BRAFV600E-targeted therapies are ineffective.
Conclusions
4-[18F]F-GLN PET selectively reflected pharmacodynamic response to BRAF inhibition when compared with 2-deoxy-2[18F]fluoro-d-glucose PET, which was decreased non-specifically for all treated cohorts, regardless of downstream pathway inhibition. These findings illustrate the utility of non-invasive PET imaging measures of glutamine uptake to selectively predict response to BRAF-targeted therapy in colon cancer and may suggest further opportunities to inform colon cancer clinical trials using targeted therapies against MAPK activation.
Similar content being viewed by others
References
Zhao Y, Butler EB, Tan M (2013) Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4:e532
Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134:703–707
Ide M (2006) Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging 50:23–27
Tagliabue L, Del Sole A (2014) Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients. Eur J Intern Med 25:6–11
McKinley ET, Smith RA, Zhao P et al (2013) 3’-Deoxy-3’-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med 54:424–430
McKinley ET, Zhao P, Coffey RJ et al (2014) 3′-Deoxy-3′-[18F]-fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. PLoS One 9:e108193
Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35:427–433
Wellen KE, Lu C, Mancuso A et al (2010) The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 24:2784–2799
Hensley CT, Wasti AT, DeBerardinis RJ (2013) Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 123:3678–3684
Liu W, Le A, Hancock C et al (2012) Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A 109:8983–8988
Gaglio D, Metallo CM, Gameiro PA et al (2011) Oncogenic K-ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 7:523
Wise DR, Ward PS, Shay JE et al (2011) Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A 108:19611–19616
Wang JB, Erickson JW, Fuji R et al (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18:207–219
Wise DR, DeBerardinis RJ, Mancuso A et al (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 105:18782–18787
Son J, Lyssiotis CA, Ying H et al (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496:101–105
van Geldermaisen M, Wang Q, Nagarajah R et al (2016) ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene 35:3201–3208
Witte D, Ali N, Carlson N et al (2002) Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res 22:2555–2557
Hassanein M, Hoeksema MD, Shiota M et al (2013) SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 19:560–570
Hassanein M, Quan J, Hoeksema MD et al (2015) Targeting SLC1A5-mediated glutamine dependence in non-small cell lung cancer. Int J Cancer 137:1587–1597
Wang Q, Hardie RA, Hoy AJ et al (2015) Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol 236:278–289
Kaira K, Sunrose Y, Arakawa K et al (2015) Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma. Histopathology 66:234–243
Gross MI, Demo SD, Dennison JB et al (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13:890–901
Lieberman BP, Ploessl K, Wang L et al (2011) PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med 52:1947–1955
Qu W, Zha Z, Ploessl K et al (2011) Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors. J Am Chem Soc 133:1122–1133
Wu Z, Zha Z, Li G et al (2014) 18F](2S,4S)-4-(3-Fluoropropyl)glutamine as a tumor imaging agent. Mol Pharm 11:3852–3866
Hassanein M, Hight MR, Buck JR et al (2016) Preclinical evaluation of 4-[(18)F]fluoroglutamine PET to assess ASCT2 expression in lung cancer. Mol Imaging Biol 18:18–23
Buck JR, Saleh S, Uddin MI et al (2012) Rapid, microwave-assisted organic synthesis of selective (V600E)BRAF inhibitors for preclinical cancer research. Tetrahedron Lett 53:4161–4165
Ayers GD, McKinley ET, Zhao P et al (2010) Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements. J Ultrasound Med 29:891–901
Hight MR, Cheung YY, Nickels ML et al (2014) A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res 20:2126–2135
Fueger BJ, Czernin J, Hildebrandt I et al (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47:999–1006
Dandekar M, Tseng JR, Gambhir SS (2007) Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 48:602–607
McKinley ET, Bugaj JE, Zhao P et al (2011) 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res 17:3332–3340
The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337
Levine AJ, Puzio-Kuter AM (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:1340–1344
Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297–308
Gao P, Tchernyshyov I, Chang TC et al (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458:762–765
Dang CV (2010) Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 70:859–862
Dang CV, Le A, Gao P (2009) MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15:6479–6483
Gordan JD, Thompson CB, Simon MC (2007) HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12:108–113
Thangavelu K, Pan CQ, Karlberg T et al (2012) Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. PNAS 109:7705–7710
Acknowledgments
These studies were supported by grants from the National Institutes of Health (R01-CA140628, P50-CA95103, 5P30-DK058404, P30-CA068485), the Kleberg Foundation, and the Vanderbilt Center for Molecular Probes. The authors wish to thank Ping Zhao for her assistance with the animal experiments, Md. Noor Tantaway for his assistance with the small animal PET acquisition, and Michael Nickels for his assistance with radio tracer production.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflicts of interest.
Electronic supplementary material
ESM 1
(PDF 206 kb)
Rights and permissions
About this article
Cite this article
Schulte, M.L., Hight, M.R., Ayers, G.D. et al. Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo . Mol Imaging Biol 19, 421–428 (2017). https://doi.org/10.1007/s11307-016-1008-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-016-1008-z